Strategic archetype of herbal medicine product (HMP) in regulated and emerging market Tripathy Swagat1,*, Murthy PN2, Patra BP3, Vikram4, Sanduria Sumit4, Dureja Harish4,* 1Dr. Reddy’s. Laboratories, Hyderabad, Telangana, India - 500034 2Royal College of Pharmacy and Health Sciences, Berhampur, India - 760002 3XIMB, Xavier Square, Jayadev Vihar, Bhubaneswar, Odisha, India - 751013 4Department of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak, India - 124001 *Corresponding Author E-mail: swagat.tripathy7@gmail.com
Online published on 20 February, 2023. Abstract Herbal Medicine Products (HMPs) are ever-present and demand still keeps on the rise, despite of fact that modern medicines are well developed. So, regulative intervention and attempts by various regulatory bodies across the globe to ensure the safety, quality, and efficacy of HMPs have been a real-time challenge. While Allopathic medicines principally depict chemical substances, and those interactions had been well-known, validated also, proper regulatory standard then relevant measures are put into action. HMPs, instead by and large consisting numerous ingredients holding multifaceted combinations along with plant constituents then frequently likewise comprise of roughly anonymous complexes, therefore, building affecting regulatory framework toward measure affecting worth about those drugs is more tricky. So, through this manuscript efforts have been made to summarize definitions, basis of formulating policies and measures pertaining on registration and regulation of herbal medicinal products (HMPs) for both regulated and emerging markets i.e., United States, India, China, Japan, and Europe. Top Keywords WHO, Herbal Medicines Products, USFDA, EMA, AYUSH, NMPA, PMDA. Top |